National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES) (ALTITUDES)
National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis
Sponsor: APICIL funding
Listed as NCT02867033, this NA trial focuses on Aggressive Fibromatosis and remains ongoing. Sponsored by APICIL funding, it has been updated 13 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting NA
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting NA
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting NA
▶ Show 8 earlier versions
-
Mar 2023 — Jun 2024 [monthly]
Active Not Recruiting NA
-
Jun 2021 — Mar 2023 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting NA
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Dec 2020 [monthly]
Recruiting NA
-
Jun 2018 — Aug 2018 [monthly]
Recruiting NA
-
Oct 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Oct 2017 [monthly]
Recruiting NA
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- APICIL funding
- Centre Oscar Lambret
- GIRCI NO
- Groupement Interrégional de Recherche Clinique et d'Innovation
- Hôpital de la Timone
- Institut Curie
- Ligue contre le cancer, France
- SOS Desmoid e.V.
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Besançon, France , Bordeaux, France , Caen, France , Clermont-Ferrand, France , Dijon, France , Grenoble, France , Lille, France , Lyon, France , Marseille, France and 16 more locations